All In Biotech

NDA 020936 · Apotex

Paxil Cr

Paroxetine Hydrochloride · Oral

Last checked: Nov 21, 2026Latest source record: Sep 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Feb 16, 1999

Approved uses

4

Original approval plus efficacy supplements

Registered trials

275

60 Phase 3, 11 recruiting

FAERS reports

58,759

35,558 serious, 3,728 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [See Warnings and Precautions ( 5.1 )] PAXIL CR is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Antidepressants increase the risk of suicidal thoughts and behavior in pediatric and young adult patients ( 5.1 ). Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). PAXIL CR is not approved for use in pediatric patients. ( 5.1 , 8.4)

What it is approved for

From the label in effect Sep 30, 2026.

PAXIL CR is indicated for the treatment of: Major depressive disorder (MDD) in adults Panic disorder (PD) in adults Social anxiety disorder (SAD) in adults Premenstrual dysphoric disorder (PMDD) in adults PAXIL CR is a selective serotonin reuptake inhibitor (SSRI) indicated for use in adults for the treatment of ( 1 ): Major depressive disorder (MDD) in adults Panic disorder (PD) in adults Social anxiety disorder (SAD) in adults Premenstrual dysphoric disorder (PMDD) in adults

Mechanism: The mechanism of action of PAXIL CR in the treatment of major depressive disorder (MDD), panic disorder (PD), social anxiety disorder (SAD), and premenstrual dysphoric disorder (PMDD) is unknown, but is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin (5-HT).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • PAXIL CR · PAROXETINE HYDROCHLORIDE EQ 37.5MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • PAXIL CR · PAROXETINE HYDROCHLORIDE EQ 12.5MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • PAXIL CR · PAROXETINE HYDROCHLORIDE EQ 25MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Paroxetine" as an intervention, any sponsor and status, largest first.

All 275 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug withdrawal syndrome5,827
  • nausea4,557
  • drug ineffective4,412
  • dizziness4,300
  • anxiety4,175
  • fatigue3,832
  • headache3,563
  • depression3,388
  • drug exposure during pregnancy3,124
  • insomnia2,934
  • weight increased2,597
  • diarrhoea2,585

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046,691
20056,081
20064,742
20072,990
20082,730
20092,644
20103,016
20113,113
20122,882
20131,735
20141,759
20153,467
20163,112
20171,936
20181,702
20191,714
20201,495
20211,367
20221,291
20231,171
20241,207
20251,095
2026812

Recalls

7 FDA enforcement reports for this application.

  • Sep 23, 2026 · Class II · Ongoing

    Failed dissolution specifications.

  • Aug 13, 2026 · Class II · Ongoing

    Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria

  • Mar 24, 2014 · Class II · Terminated

    Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.

  • Mar 24, 2014 · Class II · Terminated

    Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.

  • Mar 24, 2014 · Class II · Terminated

    Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.

  • Mar 24, 2014 · Class II · Terminated

    Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.

  • Mar 24, 2014 · Class II · Terminated

    Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Paxil Cr (Paroxetine HCl)

2024 spending

$2.1M

Beneficiaries

648

3,152 claims

Per beneficiary

$3,273

$9.61 per unit

View as table
YearSpending
2020$2,682,330
2021$2,585,096
2022$2,517,004
2023$2,545,720
2024$2,121,114

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,397 on PubMed

Sponsor: Apotex

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.